{"version":"1.0","provider_name":"FYB Financial Yearbook","provider_url":"https:\/\/www.fyb.de\/en\/","author_name":"Tatjana Anderer","author_url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/","title":"ETHYPHARM to buy Argatroban business from Mitsubishi Tanabe Pharma Group - FYB Financial Yearbook","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"UoyAAM2qsa\"><a href=\"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/\">ETHYPHARM to buy Argatroban business from Mitsubishi Tanabe Pharma Group<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.fyb.de\/en\/ethypharm-to-buy-argatroban-business-from-mitsubishi-tanabe-pharma-group\/embed\/#?secret=UoyAAM2qsa\" width=\"600\" height=\"338\" title=\"&#8220;ETHYPHARM to buy Argatroban business from Mitsubishi Tanabe Pharma Group&#8221; &#8212; FYB Financial Yearbook\" data-secret=\"UoyAAM2qsa\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2025\/07\/kai-schadbach-schadbach-rechtsanwaelte.jpg","thumbnail_width":397,"thumbnail_height":397,"description":"Frankfurt a. Main - The leading medium-sized international pharmaceutical company Ethypharm S.A.S., Saint-Cloud\/France, has concluded a purchase agreement for the rights to the European Argatroban business of Mitsubishi Tanabe Pharma Corporation, Osaka\/Japan and other companies of the Mitsubishi Tanabe Pharma Group. Due to the company structures, the complexity of the rights to the product and the involvement of other operational intermediaries for the manufacture of the Argatroban active ingredient, the transaction was carried out by way of an asset deal."}